Hi everyone I'm sharing one of our recent 16 minutes episodes here since it covers

COVID vaccines a topic that's top of mind for everyone so we wanted to make sure

that everyone had access to it in this feed where we've long

covered the coronavirus pandemic since very early on and we also answer some

questions in this episode that actually applied to both recent vaccine

announcements if you haven't subscribed already you can find

16 minutes from A6 and Z in your podcast player app and do so there. As a reminder

this is our show where we talk about the news, tease apart what's hype, what's real in the headlines,

or in this case, quote, science by press release, and we always cover where we are in the

long arc of innovation beyond the news, why it matters now.

In the episode that follows, we broke down the Pfizer and Beyond Tech News and specifically

what the Phase 3 interim trial means.

The difference between vaccine efficacy and efficiency and the significance of

MRNA vaccines now and in the future. For those who want to learn more about how

vaccines work, how they're made, phases of trials and regulation, what trade-offs are and aren't

being made for accelerated COVID development of vaccines, the where's and who's of distribution,

you can find that in a past episode we did in this feed or at

a six and z.com slash vaccines. In this episode a six and z bio general

partners, Vanite the Agarwala and Jorge Conde join me to discuss the news right after the

announcement of 90% vaccine efficacy last week but we begin by orienting where we

are right now given all the other efforts out there.

So it's important to put into context the Pfizer and use you just go to biocentric.com

...